Corden Pharma – Oligonucleotides: Promising Therapeutics with Significant Challenges


e-version image

Click HERE to download the PDF version


Matthieu Giraud Ph.D1, CHRISTIAN AHLMARK2

1. Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platform CordenPharma International

2. Associate Director, Sales & Key Account Management CordenPharma International

In recent years, interest in oligonucleotide therapeutics has resurged, as new approaches, clinical applications, advances in delivery, and a deeper biological understanding of these compounds emerge. However, expectations have been largely unfulfilled, as only three oligonucleotide drugs have been approved by the FDA for use in the United States as of August 2017.

Today, more than 200 clinical trials are registered at, and as of 2016, more than 10,000 patients will ha ...